This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Photo courtesy of UT Health San Antonio Department of Radiology) "Until about 2013, only a few radiopharmaceutical agents were used to help treat cancer patients," Vroman explained in an interview with AuntMinnie.com. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
The new criteria expand PET imaging guidance to include tau PET, incorporate updated information, and provide specific guidance to enhance diagnostic precision, treatment decisions, and patient care. This 2024 update is the first revision since the initial AUC for amyloid PET was introduced in 2013. Since then, the U.S.
Photo courtesy of UT Health San Antonio Department of Radiology) "Until about 2013, only a few radiopharmaceutical agents were used to help treat cancer patients," Vroman explained in an interview with AuntMinnie.com. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
The new criteria expand PET imaging guidance to include tau PET, incorporate updated information, and provide specific guidance to enhance diagnostic precision, treatment decisions, and patient care. This 2024 update is the first revision since the initial AUC for amyloid PET was introduced in 2013. Since then, the U.S.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content